Managing Acinetobacter baumannii infections

Tacconelli, 2018, Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis, Lancet Infect Dis, 18, 318, 10.1016/S1473-3099(17)30753-3

Tabah, 2012, Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study, Intensive Care Med, 38, 1930, 10.1007/s00134-012-2695-9

Koulenti, 2017, Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study, Eur J Clin Microbiol Infect Dis, 36, 1999, 10.1007/s10096-016-2703-z

Chung, 2011, High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia, Am J Respir Crit Care Med, 184, 1409, 10.1164/rccm.201102-0349OC

Dananche, 2018, Trends of incidence and risk factors of ventilator-associated pneumonia in elderly patients admitted to French ICUs between 2007 and 2014, Crit Care Med, 46, 869, 10.1097/CCM.0000000000003019

Villar, 2014, Epidemiologic and clinical impact of Acinetobacter baumannii colonization and infection: a reappraisal, Medicine, 93, 202, 10.1097/MD.0000000000000036

Olaechea, 2016, Characteristics and outcomes of patients admitted to Spanish ICU: a prospective observational study from the ENVIN-HELICS registry, Med Intensiva, 40, 216, 10.1016/j.medin.2015.07.003

Munoz-Price, 2013, Eighteen years of experience with Acinetobacter baumannii in a tertiary care hospital, Crit Care Med, 41, 2733, 10.1097/CCM.0b013e318298a541

Escudero, 2017, Control of an Acinetobacter baumannii multidrug resistance endemic in the ICU. Recalling the obvious, Med Intensiva, 41, 497, 10.1016/j.medin.2016.11.005

Masse, 2017, Colonization pressure as a risk factor of ICU-acquired multidrug resistant bacteria: a prospective observational study, Eur J Clin Microbiol Infect Dis, 36, 797, 10.1007/s10096-016-2863-x

Fitzpatrick, 2016, Utility of whole-genome sequencing in characterizing Acinetobacter epidemiology and analyzing hospital outbreaks, J Clin Microbiol, 54, 593, 10.1128/JCM.01818-15

Lee, 2014, Risk factors and outcome analysis of Acinetobacter baumannii complex bacteremia in critical patients, Crit Care Med, 42, 1081, 10.1097/CCM.0000000000000125

Huang, 2018, A multicenter study on the risk factors of infection caused by multidrug resistant Acinetobacter baumannii, BMC Infect Dis, 18, 11, 10.1186/s12879-017-2932-5

Dijkshoorn, 2007, An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii, Nat Rev Microbiol, 5, 939, 10.1038/nrmicro1789

Garnacho-Montero, 2010, Multiresistant Acinetobacter baumannii infections: epidemiology and management, Curr Opin Infect Dis, 23, 332, 10.1097/QCO.0b013e32833ae38b

Peleg, 2012, The success of Acinetobacter species: genetic, metabolic and virulence attributes, PLoS One, 7, e46984, 10.1371/journal.pone.0046984

Jeannot, 2014, Molecular epidemiology of carbapenem nonsusceptible Acinetobacter baumannii in France, PLoS One, 9, e115452, 10.1371/journal.pone.0115452

Poirel, 2006, Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology, Clin Microbiol Infect, 12, 826, 10.1111/j.1469-0691.2006.01456.x

Kempf, 2012, Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options, Int J Antimicrob Agents, 39, 105, 10.1016/j.ijantimicag.2011.10.004

Bonnin, 2012, Dissemination of New Delhi metallo-β-lactamase-1-producing Acinetobacter baumannii in Europe, Clin Microbiol Infect, 18, E362, 10.1111/j.1469-0691.2012.03928.x

Bonnin, 2013, Wide dissemination of GES-type carbapenemases in Acinetobacter baumannii isolates in Kuwait, Antimicrob Agents Chemother, 57, 183, 10.1128/AAC.01384-12

Yang, 2018, Molecular epidemiology and mechanism of sulbactam resistance in Acinetobacter baumannii isolates with diverse genetic backgrounds in China, Antimicrob Agents Chemother, 62, 10.1128/AAC.01947-17

Vourli, 2017, Evaluation of two automated systems for colistin susceptibility testing of carbapenem-resistant Acinetobacter baumannii clinical isolates, J Antimicrob Chemother, 72, 2528, 10.1093/jac/dkx186

Qureshi, 2015, Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance, Clin Infect Dis, 60, 1295, 10.1093/cid/civ048

Liu, 2016, Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study, Lancet Infect Dis, 16, 161, 10.1016/S1473-3099(15)00424-7

Li, 2006, Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii, Antimicrob Agents Chemother, 50, 2946, 10.1128/AAC.00103-06

Hawley, 2008, Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy, Antimicrob Agents Chemother, 52, 351, 10.1128/AAC.00766-07

Falagas, 2015, Tetracyclines for multidrug-resistant Acinetobacter baumannii infections, Int J Antimicrob Agents, 45, 455, 10.1016/j.ijantimicag.2014.12.031

Gil-Perotin, 2012, Implications of endotracheal tube biofilm in ventilator-associated pneumonia response: a state of concept, Crit Care, 16, R93, 10.1186/cc11357

Garnacho-Montero, 2016, Acinetobacter baumannii in critically ill patients: molecular epidemiology, clinical features and predictors of mortality, Enferm Infecc Microbiol Clin, 34, 551, 10.1016/j.eimc.2015.11.018

Garnacho-Montero, 2005, Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings, Intensive Care Med, 31, 649, 10.1007/s00134-005-2598-0

Garnacho-Montero, 2015, Task force on management and prevention of Acinetobacter baumannii infections in the ICU, Intensive Care Med, 41, 2057, 10.1007/s00134-015-4079-4

Bassetti, 2015, Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria, Intensive Care Med, 41, 776, 10.1007/s00134-015-3719-z

Roca, 2012, The Acinetobacter baumannii oxymoron: commensal hospital dweller turned pan-drug-resistant menace, Front Microbiol, 3, 148, 10.3389/fmicb.2012.00148

Jaruratanasirikul, 2013, Pharmacodynamics modeling to optimize dosage regimens of sulbactam, Antimicrob Agents Chemother, 57, 3441, 10.1128/AAC.00342-13

Oliveira, 2008, Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp, J Antimicrob Chemother, 61, 1369, 10.1093/jac/dkn128

Vardakas, 2018, Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis, Int J Antimicrob Agents, 51, 535, 10.1016/j.ijantimicag.2017.12.020

Horcajada, 2016, Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate, Int J Antimicrob Agents, 48, 725, 10.1016/j.ijantimicag.2016.08.020

Srinivas, 2018, Detection of colistin heteroresistance in Acinetobacter baumannii from blood and respiratory isolates, Diagn Microbiol Infect Dis, 91, 194, 10.1016/j.diagmicrobio.2018.01.028

Sandri, 2013, Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens, Clin Infect Dis, 57, 524, 10.1093/cid/cit334

Akajagbor, 2013, Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center, Clin Infect Dis, 57, 1300, 10.1093/cid/cit453

Greig, 2016, Intravenous minocycline: a review in Acinetobacter infections, Drugs, 76, 1467, 10.1007/s40265-016-0636-6

Meagher, 2005, Pharmacokinetic/pharmacodynamics profile for tigecycline: a new glycylcycline antimicrobial agent, Diagn Microbiol Infect Dis, 52, 165, 10.1016/j.diagmicrobio.2005.05.006

Burkhardt, 2009, Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint, Int J Antimicrob Agents, 34, 101, 10.1016/j.ijantimicag.2009.01.015

Chuang, 2014, Effectiveness of tigecycline-based versus colistin-based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis, BMC Infect Dis, 14, 102, 10.1186/1471-2334-14-102

Ni, 2016, Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis, Int J Antimicrob Agents, 47, 107, 10.1016/j.ijantimicag.2015.11.011

Kengkla, 2018, Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis, J Antimicrob Chemother, 73, 22, 10.1093/jac/dkx368

De Pascale, 2014, High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria, Crit Care, 18, R90, 10.1186/cc13858

Batirel, 2014, Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections, Eur J Clin Microbiol Infect Dis, 33, 1311, 10.1007/s10096-014-2070-6

Kalin, 2014, Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia, Infection, 42, 37, 10.1007/s15010-013-0495-y

Gordon, 2010, Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii, Antimicrob Agents Chemother, 54, 5316, 10.1128/AAC.00922-10

Wareham, 2011, In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii, J Antimicrob Chemother, 66, 1047, 10.1093/jac/dkr069

Galani, 2014, Colistin/daptomycin: an unconventional antimicrobial combination synergistic in vitro against multidrug-resistant Acinetobacter baumannii, Int J Antimicrob Agents, 43, 370, 10.1016/j.ijantimicag.2013.12.010

Garnacho-Montero, 2013, Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant A. baumannii, Chemotherapy, 59, 225, 10.1159/000356004

Petrosillo, 2014, Colistinglycopeptide combination in critically ill patients with Gram-negative infection: the clinical experience, Antimicrob Agents Chemother, 58, 851, 10.1128/AAC.00871-13

Durante-Mangoni, 2013, Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial, Clin Infect Dis, 57, 349, 10.1093/cid/cit253

Aydemir, 2013, Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia, Epidemiol Infect, 141, 1214, 10.1017/S095026881200194X

Sirijatuphat, 2014, Colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections: a preliminary study, Antimicrob Agents Chemother, 58, 5598, 10.1128/AAC.02435-13

Paul, 2018, Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial, Lancet Infect Dis, 18, 391, 10.1016/S1473-3099(18)30099-9

Mohammadi, 2017, Synergistic effect of colistin and rifampin against multidrug resistant Acinetobacter baumannii: a systematic review and meta-analysis, Open Microbiol J, 11, 63, 10.2174/1874285801711010063

Liu, 2014, Efficacy and safety of polymyxins for the treatment of Acinectobacter baumannii infection: a systematic review and meta-analysis, PLoS One, 9, e98091, 10.1371/journal.pone.0098091

Jung, 2017, Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis, Crit Care, 21, 319, 10.1186/s13054-017-1916-6